| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/20/2010 | CA2278345C Monohydric alcohol derived urethanes and their use in cosmetic formulations |
| 04/20/2010 | CA2268358C Hormonal composition consisting of an oestrogen compound and of a progestational compound |
| 04/20/2010 | CA2229078C Pharmaceutical composition containing il-10 |
| 04/20/2010 | CA2181433C Materials and methods for management of hyperacute rejection in human xenotransplantation |
| 04/20/2010 | CA2180872C Composition containing nucleic acids, preparation and uses |
| 04/20/2010 | CA1341603C Acidic polysaccharide esters and process for their preparation |
| 04/15/2010 | WO2010042933A2 Inhibition and treatment of prostate cancer metastasis |
| 04/15/2010 | WO2010042930A1 Methods for treating vasomotor symptoms in castrated prostatic cancer patients with low dose cyproterone acetate |
| 04/15/2010 | WO2010042925A2 Compositions and methods for treating alcohol use disorders, pain and other diseases |
| 04/15/2010 | WO2010042892A1 Pyrrolidine compounds which inhibit beta-secretase activity and methods of use thereof |
| 04/15/2010 | WO2010042886A2 Pyrone analogs for therapeutic treatment |
| 04/15/2010 | WO2010042868A2 Methods for treating obesity |
| 04/15/2010 | WO2010042867A2 Activators of human pyruvate kinase |
| 04/15/2010 | WO2010042851A1 Antibacterial aminoglycoside analogs |
| 04/15/2010 | WO2010042850A1 Antibacterial aminoglycoside analogs |
| 04/15/2010 | WO2010042843A2 Composition and method for treating dry eye syndrome |
| 04/15/2010 | WO2010042841A1 Combination therapies for the treatment of degenerative inflammatory conditions of the nervous system |
| 04/15/2010 | WO2010042834A1 A method of inhibiting hepatitis c virus by combination of a 5,6-dihydro-1h-pyridin-2-one and one or more additional antiviral compounds |
| 04/15/2010 | WO2010042830A1 5,6-dihydro-1h-pyridin-2-one compounds |
| 04/15/2010 | WO2010042799A2 Novel chimeric ligand-gated ion channels and methods of use thereof |
| 04/15/2010 | WO2010042788A1 Method of inducing negative chemotaxis |
| 04/15/2010 | WO2010042780A2 Methods and compositions for treating status epilepticus and seizures causing status epilepticus |
| 04/15/2010 | WO2010042759A2 Gaba conjugates and methods of use thereof |
| 04/15/2010 | WO2010042758A2 Oxazole-pyridazine-oxazole alpha-helix mimetic |
| 04/15/2010 | WO2010042755A2 Chimeric therapeutics, compositions, and methods for using same |
| 04/15/2010 | WO2010042714A1 Combination therapy comprising angiotensin receptor blockers and vasopressin receptor antagonists |
| 04/15/2010 | WO2010042701A2 Corticosteroid compositions and methods of treatments thereof |
| 04/15/2010 | WO2010042699A1 Imidazopyridazinecarbonitriles useful as kinase inhibitors |
| 04/15/2010 | WO2010042685A2 Inhibitors of the atb(0,+) transporter and uses thereof |
| 04/15/2010 | WO2010042684A1 Pyrrolotriazine kinase inhibitors |
| 04/15/2010 | WO2010042683A1 Treating hepatitis c virus infection with over-expression of microrna-196 |
| 04/15/2010 | WO2010042682A1 Azolotriazinone melanin concentrating hormone receptor-1 antagonists |
| 04/15/2010 | WO2010042674A1 Pyrrolone melanin concentrating hormone receptor-1 antagonists |
| 04/15/2010 | WO2010042657A1 Use of diindolylmethane (dim) compounds and derivatives as neuroprotective agents |
| 04/15/2010 | WO2010042652A2 Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors |
| 04/15/2010 | WO2010042649A2 PHTHALAZINE COMPOUNDS AS p38 MAP KINASE MODULATORS AND METHODS OF USE THEREOF |
| 04/15/2010 | WO2010042646A1 Aza- and diaza-phthalazine compounds as p38 map kinase modulators and methods of use thereof |
| 04/15/2010 | WO2010042642A1 Calcium receptor modulating agents |
| 04/15/2010 | WO2010042636A2 Telomerase inhibitors and methods of use thereof |
| 04/15/2010 | WO2010042633A2 Naringenin complexes and methods of use thereof |
| 04/15/2010 | WO2010042626A1 1-phenylpyrrole compounds |
| 04/15/2010 | WO2010042622A1 Atropisomers of (hydroxyalkyl) pyrrole derivatives |
| 04/15/2010 | WO2010042612A1 Transdermal delivery |
| 04/15/2010 | WO2010042603A1 Amyloid and depression |
| 04/15/2010 | WO2010042600A2 Photo-activatable therapeutic agents and methods of using |
| 04/15/2010 | WO2010042596A2 Photo-activated protecting groups |
| 04/15/2010 | WO2010042553A1 Aerosol fluoroquinolone formulations for improved pharmacokinetics |
| 04/15/2010 | WO2010042549A1 Inhalation of levofloxacin for reducing lung inflammation |
| 04/15/2010 | WO2010042547A1 Compositions and methods for inhibiting expression of an rna from west nile virus |
| 04/15/2010 | WO2010042543A2 Use of inhibitors of toll-like receptors in the prevention and treatment of hypercholesterolemia and hyperlipidemia and diseases related thereto |
| 04/15/2010 | WO2010042538A1 Diagnosis and treatment of back pain |
| 04/15/2010 | WO2010042500A2 Heat shock protein 90 inhibitors, methods of preparing same, and methods for their use |
| 04/15/2010 | WO2010042499A1 Stable solutions of orlistat for pharmaceutical dosage forms |
| 04/15/2010 | WO2010042489A2 Aminoquinoline derived heat shock protein 90 inhibitors, methods of preparing same, and methods for their use |
| 04/15/2010 | WO2010042477A1 Benzodioxan analogues as alpha2c adrenergic receptor modulators |
| 04/15/2010 | WO2010042475A1 Spiroaminooxazoline analogues as alpha2c adrenergic receptor modulators |
| 04/15/2010 | WO2010042473A1 Biaryl spiroaminooxazoline analogues as alpha2c adrenergic receptor modulators |
| 04/15/2010 | WO2010042459A1 Topical formulations with a tertiary amine oxide |
| 04/15/2010 | WO2010042445A1 Carbazole compounds and therapeutic uses of the compounds |
| 04/15/2010 | WO2010042432A1 Microspheres for the sustained release of octreotide with a low initial burst |
| 04/15/2010 | WO2010042419A1 Chewing gum containing low dose amounts of water soluble vitamins |
| 04/15/2010 | WO2010042399A1 Natural preservative alternatives and compositions containing same |
| 04/15/2010 | WO2010042395A1 Benzimidazole anthelmintic compositions |
| 04/15/2010 | WO2010042392A2 Hiv integrase inhibitors |
| 04/15/2010 | WO2010042391A2 Hiv integrase inhibitors |
| 04/15/2010 | WO2010042337A1 Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity |
| 04/15/2010 | WO2010042292A1 Method for selectively inhibiting the activity of acat1 in the treatment of alzheimer's disease |
| 04/15/2010 | WO2010042241A1 Cross- linked fatty acid-based biomaterials |
| 04/15/2010 | WO2010042229A2 Treatment of chronic fatigue syndrome using selective agonists of toll-like receptor 3 (tlr3) |
| 04/15/2010 | WO2010042212A2 Methods for treating or preventing pain using spicamycin derivatives |
| 04/15/2010 | WO2010042163A2 Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and sirt1, and methods of treating disorders |
| 04/15/2010 | WO2010042152A2 Amorphous rotigotine transdermal system |
| 04/15/2010 | WO2010042120A1 Process for the synthesis of amphetamine derivatives |
| 04/15/2010 | WO2010042030A1 Aspartyl protease inhibitors |
| 04/15/2010 | WO2010041983A1 Substituted 3-arylsulfonyl-pyrazolo[1,5-a]pyrimidines, serotonin 5-ht6 receptor antagonists and methods for the production and use thereof |
| 04/15/2010 | WO2010041963A1 Treating or preventing gout |
| 04/15/2010 | WO2010041908A2 Novel use of panduratin derivative or boesenbergia pandurata extract |
| 04/15/2010 | WO2010041777A1 Anti-halitosis composition comprising panduratin derivatives |
| 04/15/2010 | WO2010041748A1 Fluorene compound and use thereof for medical purposes |
| 04/15/2010 | WO2010041746A1 Helicobacter pylori bacterium proliferation inhibitor |
| 04/15/2010 | WO2010041726A1 Substituted tricyclic heteroaryl compound |
| 04/15/2010 | WO2010041711A1 Isoquinoline derivative, and pde inhibitor comprising same as active ingredient |
| 04/15/2010 | WO2010041703A1 Anti-sars coronavirus agent, and product containing anti-sars coronavirus agent |
| 04/15/2010 | WO2010041684A1 Tacrolimus preparation for external applications |
| 04/15/2010 | WO2010041681A1 Novel sominone derivative |
| 04/15/2010 | WO2010041647A1 Physical endurance improving agent, anti-fatigue agent or fatigue recovering agent comprising amino acid composition as active ingredient |
| 04/15/2010 | WO2010041618A1 Pharmaceutical composition for prevention or treatment of hearing loss and secondary symptoms of hearing loss |
| 04/15/2010 | WO2010041569A1 Indazole compound |
| 04/15/2010 | WO2010041568A1 Indazole derivative |
| 04/15/2010 | WO2010041459A1 Method for quantitative analysis of drug metabolite and analyzer |
| 04/15/2010 | WO2010041449A1 Anti-allergic agent comprising rxr agonist as active ingredient |
| 04/15/2010 | WO2010041410A1 Agent for suppressing increases in cholesterol |
| 04/15/2010 | WO2010041405A1 Prophylactic/therapeutic agent for depression |
| 04/15/2010 | WO2010041401A1 Protein phosphatase inhibitor |
| 04/15/2010 | WO2010041400A1 Biofilm formation inhibitor |
| 04/15/2010 | WO2010041290A1 Natural molecules extracted from bergamot tissues, extraction process and pharmaceutical use |
| 04/15/2010 | WO2010041288A1 Use of l-kynurenine and derivatives thereof for the prevention and treatment of diabetes mellitus type 1 |
| 04/15/2010 | WO2010041277A2 Stable pharmaceutical compositions of montelukast or its salts or solvates or hydrates |
| 04/15/2010 | WO2010041276A1 Pharmaceutical compositions comprising amorphous esomeprazole, dosage forms and process thereof |
| 04/15/2010 | WO2010041256A2 A composition of matter comprising liposomes embedded in a polymeric matrix and methods of using same |